Alimera Sciences, Inc. (NASDAQ:ALIM)

CAPS Rating: 2 out of 5

Results 1 - 10 of 10

Recs

0
Member Avatar clangmead (25.46) Submitted: 8/25/2015 1:37:04 PM : Outperform Start Price: $3.13 ALIM Score: +6.06

mp1

Recs

0
Member Avatar pchop12316 (82.74) Submitted: 8/25/2015 10:54:38 AM : Outperform Start Price: $3.07 ALIM Score: +9.25

Yes, Yes

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:12:18 PM : Underperform Start Price: $5.10 ALIM Score: +49.89

Short. Biopharma. $0 Revenues. Consistent share dilution.

Recs

0
Member Avatar rielfireflame (< 20) Submitted: 5/14/2013 12:01:17 AM : Outperform Start Price: $4.00 ALIM Score: -35.73

This stock has been growing over the past few weeks. It seems that the growth is constant and should continue to grow over the next few weeks.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:49:24 PM : Outperform Start Price: $4.23 ALIM Score: -63.50

went up 244% for portefeille.

Recs

0
Member Avatar trockn (< 20) Submitted: 3/10/2012 11:14:03 AM : Outperform Start Price: $4.00 ALIM Score: -58.85

This is a huge need in Ophthalmology patient care. Patients are enduring numerous injections into the eye to decrease edema and the progressive damage it can create. This time-released med will last a long time while decreasing risk and cost to the patient.

Recs

0
Member Avatar Jemabogado (< 20) Submitted: 11/13/2011 4:24:41 PM : Outperform Start Price: $2.03 ALIM Score: +11.57

European approval will help lift it from the basement of FDA rejection!

Recs

0
Member Avatar FUZZYMINKINS (< 20) Submitted: 5/21/2011 10:51:50 AM : Outperform Start Price: $8.42 ALIM Score: -106.95

Diabetes Diabetes Diabetes. americans are unhealthy

Recs

0
Member Avatar TMFBiologyFool (96.78) Submitted: 1/24/2011 1:47:55 PM : Outperform Start Price: $8.90 ALIM Score: -115.65

First FDA rejection was fairly benign. Investors will come back as second decision approaches.

Recs

0
Member Avatar Brent2223 (32.32) Submitted: 12/31/2010 10:51:37 AM : Outperform Start Price: $10.13 ALIM Score: -124.53

oversold on FDA news

Results 1 - 10 of 10

Featured Broker Partners


Advertisement